Lobe Sciences Ltd.
LOBEF · OTC
5/31/2025 | 2/28/2025 | 11/30/2024 | 8/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.09 | 0.01 | -0.00 |
| FCF Yield | -6.57% | -6.20% | -8.45% | -0.42% |
| EV / EBITDA | -0.73 | -13.14 | -7.65 | -1.82 |
| Quality | ||||
| ROIC | -17.96% | 39.92% | 41.22% | -127.75% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.41 | 0.52 | 0.30 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 408,269.49% | 588,871.68% |
| Free Cash Flow Growth | -11.16% | -51.08% | -1,604.66% | 95.57% |
| Safety | ||||
| Net Debt / EBITDA | 5.53 | -3.47 | -3.02 | -0.56 |
| Interest Coverage | -7.42 | -4.71 | -5.21 | 16.37 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -4,584.29 |